DiObex, Inc., is a privately held biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin- induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and in a convenient disposable subcutaneous delivery device. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease.
View Top Employees from DiObex , Inc.Website | http://www.diobex.com |
Employees | View employees |
Founded | 2003 |
Address | 600 Townsend St. Ste. 271, San Francisco, California 94103, US |
Phone | (415) 551-0400 |
Industry | Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Medical |
Competitors | Alkermes, Amylin Pharmaceuticals, Cellerant Therapeutics, ConjuChem, Keryx Biopharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular DiObex , Inc. employee's phone or email?
DiObex , Inc. is based in San Francisco, California.
The NAICS codes for DiObex , Inc. are [3254, 325, 32].
The SIC codes for DiObex , Inc. are [28, 283].